Literature DB >> 34016269

Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: JACC Focus Seminar 5/5.

Silvia G Priori1, Andrea Mazzanti2, Demetrio J Santiago3, Deni Kukavica4, Alessandro Trancuccio4, Jason C Kovacic5.   

Abstract

In this final of a 5-part Focus Seminar series on precision medicine, we focus on catecholaminergic polymorphic ventricular tachycardia (CPVT). This focus on CPVT allows us to take a "deep dive" and explore the full extent of the precision medicine opportunities for a single cardiovascular condition at a level that was not possible in the preceding articles. As a new paradigm presented in this article, it has become clear that CPVT can occur as either a typical or atypical form. Although there is a degree of overlap between the typical and atypical forms, it is notable that they arise due to different underlying genetic changes, likely exhibiting differing mechanisms of action, and presenting with different phenotypic features. The recognition of these differing forms of CPVT and their different etiologies and mechanisms is an important step toward implementing rapidly emerging precision medicine approaches that will tailor novel therapies to specific gene defects.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular; catecholaminergic polymorphic ventricular tachycardia precision medicine; genetics

Year:  2021        PMID: 34016269     DOI: 10.1016/j.jacc.2020.12.073

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  How does flecainide impact RyR2 channel function?

Authors:  Samantha C Salvage; Christopher L-H Huang; James A Fraser; Angela F Dulhunty
Journal:  J Gen Physiol       Date:  2022-06-17       Impact factor: 4.000

Review 2.  Therapeutic Approaches of Ryanodine Receptor-Associated Heart Diseases.

Authors:  Norbert Szentandrássy; Zsuzsanna É Magyar; Judit Hevesi; Tamás Bányász; Péter P Nánási; János Almássy
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

3.  Molecular Changes in the Cardiac RyR2 With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

Authors:  Angela F Dulhunty
Journal:  Front Physiol       Date:  2022-02-10       Impact factor: 4.566

Review 4.  Molecular, Subcellular, and Arrhythmogenic Mechanisms in Genetic RyR2 Disease.

Authors:  Ewan Douglas Fowler; Spyros Zissimopoulos
Journal:  Biomolecules       Date:  2022-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.